News and Press

December 17, 2014

Cerulean Announces First Patient Dosed with CRLX301 in Phase 1/2a Trial in Advanced Solid Tumors

Read more →

This page contains press releases issued in the past by Cerulean Pharma Inc. and is being provided for your information only. On the date released, some of the press releases may have contained statements that were then “forward-looking statements” based upon then current expectations, forecasts and assumptions that involved risks and uncertainties that could cause actual outcomes and results to differ materially. Cerulean Pharma Inc. disclaims any intention or obligation to update or revise the contents of this page, including, but not limited to, any forward-looking statements made at the time the information was first released, whether as a result of new information, future events or otherwise.

Featured News

Some links provided below will bring you to third party websites. Cerulean Pharma Inc. assumes no liability for information or statements you may encounter on the Internet outside of this website.

View by year:

2013 2012 2011 2010